AI in Genomics Explained: What Enterprises Need to Know in 2026

Executive Summary

NEW YORK, 2026 — Artificial intelligence has moved from experimental promise to operational reality in genomics, the science of reading, interpreting and acting on genetic data. The convergence of falling sequencing costs, foundation models trained on biological data, and GPU-accelerated pipelines has created a sector where machine learning now drives measurable revenue and clinical outcomes. McKinsey estimates generative AI alone could unlock $60 billion to $110 billion annually in economic value for pharmaceutical and medical-products firms. Meanwhile, named operators such as Tempus AI, Illumina, Recursion Pharmaceuticals and GeneDx are demonstrating that AI-genomics is no longer a research curiosity but a commercial engine. This guide explains what AI in genomics is, how it works across discovery and diagnostics, who the leading players are, and what enterprise decision-makers should weigh before committing capital.

Key Takeaways

• McKinsey values the generative-AI opportunity in pharma and medical products at $60–110 billion per year, part of a broader bio-revolution sized at up to $4 trillion annually over 10–20 years.
• Tempus AI reported fourth-quarter 2025 revenue of $367.2 million, up 83% year-over-year, and issued 2026 guidance of roughly $1.59 billion — the clearest proof of AI-genomics revenue at scale.
• Illumina and NVIDIA are collaborating to run DRAGEN algorithms on GPUs, embedding proprietary AI models such as SpliceAI and PrimateAI-3D into multiomic workflows.
• Recursion Pharmaceuticals advanced a drug candidate from target to IND-enabling studies in under 18 months, which the company says is more than twice as fast as the industry average.
• Roughly 75% of life-sciences leaders surveyed by McKinsey lack a comprehensive gen-AI vision or strategic roadmap — the adoption gap remains the central risk.
• Clinical genomics deployments, including rapid whole-genome sequencing in neonatal intensive care, are shortening rare-disease diagnosis from years to days.

What Is AI in Genomics?

Genomics is the study of an organism's complete set of DNA, including how genes function and interact. AI in genomics refers to the application of machine learning and, increasingly, foundation models to the enormous, heterogeneous datasets that sequencing produces. As McKinsey describes it, machine learning "analyzes large, heterogeneous data sets such as genomics, imaging, electronic health records, and laboratory results to surface patterns that inform R&D decisions."

The practical value emerges in two domains. In discovery, models predict compound activity and identify disease subtypes and biomarkers before laboratory resources are committed. In the clinic, models interpret genetic variants — distinguishing benign changes from disease-causing mutations — at a speed and consistency human analysts cannot match. Illumina's SpliceAI, PrimateAI-3D and Emedgene explainable-AI algorithms exemplify this variant-interpretation layer, and DRAGEN v4.5 now supports germline, oncology and multiomic assays.

Market Analysis: The Economic Thesis

The economic case for AI in genomics rests on the punishing economics of drug development. McKinsey's 2025 R&D analysis notes that nearly 70% of pharma R&D spending concentrates in clinical development, clinical success rates hover around 13% for assets entering Phase I, and the cost per successful new molecular entity has climbed from roughly $2.5 billion in 2016 to $4 billion today. AI's promise is to compress timelines and raise hit rates at each stage.

The table below summarises the headline figures verified across authoritative sources.

Related: Genomics Statistics: Market Momentum, Data Scale, and Clinical Adoption

The recurring caveat is execution. In McKinsey's survey of more than 100 pharma and medtech leaders, all had experimented with generative AI by late summer 2024, yet only 32% had begun scaling, and about 75% lacked a comprehensive vision or strategic roadmap with defined success measures. The technology is proven; organisational readiness is not.

Deep Dive: AI-Driven Diagnostics at Commercial Scale

Tempus AI is the clearest evidence that AI-genomics generates real revenue. The company reported fourth-quarter 2025 revenue of $367.2 million, up 83% year-over-year, with diagnostics revenue of $266.9 million growing 121.6%, driven by 29% oncology volume growth. Tempus ended the year with over $1.1 billion in total remaining contract value and 126% net revenue retention, and its first-quarter 2026 revenue reached $348.1 million, up 36.1%.

For deeper context, see our Genomics analysis: "Bloomberg Intelligence Sees Genomics Reaching $90-120 Billion by 2030".

Crucially, the AI is doing clinical work. A Tempus study demonstrated that its AI-driven Immune Profile Score more accurately predicts immunotherapy outcomes than conventional biomarkers, identifying potential responders — including 13% of colorectal and 17% of rare-cancer patients — who would otherwise be overlooked. Named deployments include selection by Northwestern Medicine to expand genomic testing across its oncology service line, plus multi-year collaborations with Merck and Gilead built around its Lens platform.

At the infrastructure layer, Illumina and NVIDIA announced at the January 2025 JP Morgan Healthcare Conference a collaboration to accelerate multiomic analysis, initially enabling DRAGEN algorithms on NVIDIA GPUs. NVIDIA simultaneously unveiled partnerships with IQVIA, Mayo Clinic and the Arc Institute — with Mayo contributing a dataset of 20 million whole-slide images and 10 million patient records to train pathology foundation models. This mirrors the accelerated-compute demand reshaping other frontiers of AI, from autonomous driving to media production, where VCs are accelerating bets in AI filmmaking.

Additional coverage: Emerging Genetics Technologies That Will Dominate 2026

Deep Dive: Compressing Drug Discovery Timelines

Recursion Pharmaceuticals illustrates AI's impact upstream. Its machine-learning genomics screen identified and advanced REC-1245, a potential first-in-class RBM39 degrader, moving from target identification to IND-enabling studies in under 18 months — which Recursion says is more than twice as fast as the industry average. In partnership with Roche and Genentech, Recursion built what it describes as the first whole-genome CRISPR knockout map generated from iPSC-derived neuronal cells, tied to a $30 million milestone. The company reported 2025 revenue of $74.7 million, $754 million in cash with runway into early 2028, and, according to Recursion, a clinical proof-of-concept showing a 43% median reduction in polyp burden (n=12 evaluable patients) at 12 weeks in a Phase 2 study for Familial Adenomatous Polyposis.

In clinical genomics, GeneDx announced ultra-rapid whole-genome sequencing in February 2025 (with ordering availability from March 2025), targeting neonatal intensive-care units where rapid diagnosis of critically ill infants can be decisive. These deployments compress rare-disease diagnostic odysseys that historically spanned years into a matter of days. Just as autonomous systems are being validated in high-stakes environments — from Tesla, Ford and GM's autonomous AI programmes — genomic AI is being held to clinical-grade evidence standards by regulators.

Related: Top 10 Genomics and Genetics Startups to Watch in 2026 in UK, Europe, US, Canada, China, India, Saudi, UAE and Brazil

Competitive Landscape

The market spans discovery-focused biotech, diagnostics operators, sequencing incumbents and compute providers. The table below maps the leading verified players and their primary AI-genomics role.

Practical Business Implications

For enterprise leaders, three implications follow. First, data strategy is the moat: the value in genomic AI accrues to those with proprietary, well-curated, multimodal datasets — Tempus's Lens platform and Mayo's pathology archive are competitive assets precisely because they are hard to replicate. Second, the adoption gap is a leadership problem, not a technology problem; McKinsey's finding that 75% of firms lack a roadmap suggests governance, talent and success metrics — not model access — are the binding constraints. Third, security and compliance are non-negotiable given the sensitivity of genetic data. As enterprises scale AI, they should study parallel disciplines such as the top AI security priorities for 2026 and the consolidation exemplified by CrowdStrike's acquisition strategy. Workforce transformation is equally material; the reskilling patterns emerging in telecoms workforce demand foreshadow the bioinformatics talent competition ahead.

For deeper context, see our Health Tech analysis: "Why Health Systems Are Scaling Digital Care in 2026, According to McKinsey and Gartner".

Forward Outlook

Through 2026 and beyond, expect three trajectories. Foundation models purpose-built for biology — including genome-scale models emerging from firms like Google DeepMind and the Arc Institute — will move interpretation from narrow, task-specific tools toward general-purpose reasoning over sequence data. Reimbursement and regulatory clarity will determine which diagnostic applications scale; the FDA's evolving posture on AI-enabled medical devices is a decisive variable. And the commercial gap between experimenters and scalers will widen, rewarding organisations that pair proprietary data with disciplined operating models. The economics are compelling, the deployments are real, and the constraint is increasingly organisational rather than technical.

Frequently Asked Questions

What is AI in genomics in simple terms?

It is the use of machine learning to read and interpret the vast datasets produced by DNA sequencing — identifying disease-causing variants, predicting drug responses, and surfacing biomarkers faster and more consistently than manual analysis.

How large is the economic opportunity?

McKinsey estimates generative AI could unlock $60–110 billion annually for pharma and medical products, within a broader bio-revolution opportunity of up to $4 trillion a year over the next 10–20 years.

Which companies are proving commercial value?

Tempus AI is the clearest example, with FY2026 revenue guidance around $1.59 billion. Illumina, Recursion Pharmaceuticals, GeneDx and NVIDIA are named operators across diagnostics, discovery and infrastructure.

What is the biggest barrier to adoption?

Organisational readiness. McKinsey found that while all surveyed life-sciences leaders had experimented with generative AI, only 32% were scaling it and roughly 75% lacked a comprehensive strategic roadmap.

How is AI changing rare-disease diagnosis?

Rapid whole-genome sequencing paired with AI variant interpretation — such as GeneDx's ultraRapid offering for neonatal intensive care — can compress diagnostic timelines from years to days for critically ill patients.

Sources include company disclosures, regulatory filings, analyst reports, and industry briefings.

Related Coverage

• More Genomics Analysis
• Latest Technology News

Analysis based on company announcements, investor disclosures, regulatory filings, Reuters, Bloomberg, Financial Times, CNBC, SEC documentation, and publicly available market data as of publication.